{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:53:02Z","timestamp":1793933582468,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The purposes of this study were to evaluate the association between total testosterone (TT) deficiency and weakness on multimorbidity in men. Analyses were performed to examine the prevalence of multimobidity among young, middle-aged, and older men, with and without testosterone deficiency. Multivariate logistic models were also\u00a0used to determine the association between age-specific TT tertiles and multimorbidity, adjusting for key sociodemographic variables, as well as a secondary analysis adjusted for grip strength. Multimorbidity was more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% vs 55.2%; p\u2009&lt;\u20090.001); however, differences were only seen within young (testosterone deficiency: 36.4%; normal TT: 13.5%; p\u2009&lt;\u20090.001) and older men (testosterone deficiency: 75.0%; normal TT: 61.5%; p\u2009&lt;\u20090.001). Robust associations were found between the age-specific low-TT (OR: 2.87; 95%CI: 2.14\u20133.83) and moderate-TT (OR: 1.67; 95%CI: 1.27\u20132.20) tertiles (reference high-TT) and multimorbidity. Secondary analysis demonstrated that both low TT (OR: 1.82; 95%CI: 1.29\u20132.55) and moderate-TT (OR: 1.31; 95%CI: 1.01\u20131.69) were associated with multimorbidity, even after adjusting for obesity (OR: 1.75; 95%CI: 1.07\u20132.87) and NGS (OR: 1.21 per 0.05 unit lower NGS). Low TT and weakness in men were independently associated with multimorbidity at all ages; however, multimorbidity was more prevalent among young and older men with testosterone deficiency.<\/jats:p>","DOI":"10.1038\/s41598-018-24347-6","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T07:13:31Z","timestamp":1522998811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Testosterone Deficiency, Weakness, and Multimorbidity in Men"],"prefix":"10.1038","volume":"8","author":[{"given":"Mark D.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Belakovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-8649","authenticated-orcid":false,"given":"Joshua F.","family":"Yarrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"24347_CR1","doi-asserted-by":"crossref","unstructured":"Harman, S. M. et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724\u2013731, 86.2. 7219 (2001).","DOI":"10.1210\/jcem.86.2.7219"},{"key":"24347_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1055\/s-0034-1395569","volume":"47","author":"T Deutschbein","year":"2015","unstructured":"Deutschbein, T., Mann, K. & Petersenn, S. Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Influence of Age and Body Mass Index and Establishment of Sex-Specific Reference Ranges. Horm. Metab Res. 47, 846\u2013854 (2015).","journal-title":"Horm. Metab Res."},{"key":"24347_CR3","doi-asserted-by":"crossref","unstructured":"Borst, S. E. & Yarrow, J. F. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. Am J. Physiol. Endo.Metab. 308 (2015).","DOI":"10.1152\/ajpendo.00111.2015"},{"key":"24347_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/EJE-13-0321","volume":"169","author":"V Muraleedharan","year":"2013","unstructured":"Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S. & Jones, T. H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 169, 725\u2013733 (2013).","journal-title":"Eur J Endocrinol."},{"key":"24347_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1210\/jc.2008-2650","volume":"94","author":"A Tivesten","year":"2009","unstructured":"Tivesten, A. et al. Low serum testosterone and estradiol predict mortality in elderly men. J. Clin. Endocrinol. Metab. 94, 2482\u20132488 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"24347_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1210\/jc.2007-1792","volume":"93","author":"GA Laughlin","year":"2008","unstructured":"Laughlin, G. A., Barrett-Connor, E. & Bergstrom, J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68\u201375, https:\/\/doi.org\/10.1210\/jc.2007-1792 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"24347_CR7","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1210\/jc.2011-1137","volume":"96","author":"AB Araujo","year":"2011","unstructured":"Araujo, A. B. et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 3007\u20133019 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"24347_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/ijcp.12779","volume":"70","author":"G Hackett","year":"2016","unstructured":"Hackett, G. et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int. J Clin Pract. 70, 244\u2013253 (2016).","journal-title":"Int. J Clin Pract."},{"key":"24347_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2337\/dc08-2216","volume":"32","author":"LA Colangelo","year":"2009","unstructured":"Colangelo, L. A. et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes care. 32, 1049\u20131051 (2009).","journal-title":"Diabetes care."},{"key":"24347_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1365-2605.2010.01117.x","volume":"34","author":"G Corona","year":"2011","unstructured":"Corona, G. et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 34, 528\u2013540, https:\/\/doi.org\/10.1111\/j.1365-2605.2010.01117.x (2011).","journal-title":"Int J Androl."},{"key":"24347_CR11","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/hrt.2010.210757","volume":"97","author":"JB Ruige","year":"2011","unstructured":"Ruige, J. B., Mahmoud, A. M., De Bacquer, D. & Kaufman, J. M. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 97, 870\u2013875 (2011).","journal-title":"Heart."},{"key":"24347_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrurol.2015.238","volume":"12","author":"A Aversa","year":"2015","unstructured":"Aversa, A. & Morgentaler, A. The practical management of testosterone deficiency in men. Nat Rev Urol. 12, 641\u2013650 (2015).","journal-title":"Nat Rev Urol."},{"key":"24347_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1210\/er.2001-0025","volume":"24","author":"FC Wu","year":"2003","unstructured":"Wu, F. C. & von Eckardstein, A. Androgens and coronary artery disease. Endocr Rev. 24, 183\u2013217 (2003).","journal-title":"Endocr Rev."},{"key":"24347_CR14","unstructured":"Heron, M. Deaths: Leading causes for 2014., (National Center for Health Statistics, Hyattsville, MD, 2016)."},{"key":"24347_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1210\/jc.2016-2935","volume":"102","author":"T Travison","year":"2017","unstructured":"Travison, T. et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the USA and Europe. J. Clin. Endocrinol. Metab. 102, 1161\u20131173 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"24347_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2337\/dc07-1390","volume":"31","author":"T Sairenchi","year":"2008","unstructured":"Sairenchi, T. et al. Underweight as a predictor of diabetes in older adults: a large cohort study. Diabetes care. 31, 583\u2013584 (2008).","journal-title":"Diabetes care."},{"key":"24347_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 16, 606\u2013613 (2001).","journal-title":"J Gen Intern Med."},{"key":"24347_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2337\/dc09-9033","volume":"32","author":"C International Expert","year":"2009","unstructured":"International Expert, C. et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes care. 32, 1327\u20131334 (2009).","journal-title":"Diabetes care."},{"key":"24347_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/gerona\/glw035","volume":"71","author":"AR Quinones","year":"2016","unstructured":"Quinones, A. R., Markwardt, S. & Botoseneanu, A. Multimorbidity Combinations and Disability in Older Adults. J Gerontol a-Biol. 71, 823\u2013830 (2016).","journal-title":"J Gerontol a-Biol."},{"key":"24347_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/epirev\/mxs009","volume":"35","author":"ME Salive","year":"2013","unstructured":"Salive, M. E. Multimorbidity in Older Adults. Epidemiologic reviews. 35, 75\u201383 (2013).","journal-title":"Epidemiologic reviews."},{"key":"24347_CR21","first-page":"355","volume":"72","author":"M Espeland","year":"2016","unstructured":"Espeland, M. et al. Clinical Trials Targeting Aging and Age-Related Multimorbidity. J Gerontol, Series A. 72, 355\u2013361 (2016).","journal-title":"J Gerontol, Series A."},{"key":"24347_CR22","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1210\/jc.2009-2354","volume":"95","author":"S Bhasin","year":"2010","unstructured":"Bhasin, S. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 2536\u20132559 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"24347_CR23","unstructured":"NHANES. Muscle Strength Procedures Manual, http:\/\/www.cdc.gov\/nchs\/data\/nhanes\/nhanes_11_12\/Muscle_Strength_Proc_Manual.pdf (2011)."},{"key":"24347_CR24","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/CIRCULATIONAHA.107.719005","volume":"116","author":"KT Khaw","year":"2007","unstructured":"Khaw, K. T. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 116, 2694\u20132701 (2007).","journal-title":"Circulation."},{"key":"24347_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40279-015-0463-z","volume":"46","author":"MD Peterson","year":"2016","unstructured":"Peterson, M. D., Zhang, P., Choksi, P., Markides, K. S. & Al Snih, S. Muscle Weakness Thresholds for Prediction of Diabetes in Adults. Sports Med. 46, 619\u2013628 (2016).","journal-title":"Sports Med."},{"key":"24347_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(14)62000-6","volume":"386","author":"DP Leong","year":"2015","unstructured":"Leong, D. P. et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 386, 266\u2013273 (2015).","journal-title":"Lancet."},{"key":"24347_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-11-0447","volume":"165","author":"G Corona","year":"2011","unstructured":"Corona, G. et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 165, 687\u2013701 (2011).","journal-title":"Eur J Endocrinol."},{"issue":"Suppl 3","key":"24347_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey, W. T. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients withObesity. Endocr Pract. 22(Suppl 3), 1\u2013203 (2016).","journal-title":"Endocr Pract."},{"key":"24347_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1000485","volume":"363","author":"S Basaria","year":"2010","unstructured":"Basaria, S. et al. Adverse Events Associated with Testosterone Administration. New Engl J Med. 363, 109\u2013122 (2010).","journal-title":"New Engl J Med."},{"key":"24347_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.eururo.2010.12.027","volume":"59","author":"A Morgentaler","year":"2011","unstructured":"Morgentaler, A. Words of wisdom. Re: Adverse events associated with testosterone administration. European urology. 59, 465 (2011).","journal-title":"European urology."},{"key":"24347_CR31","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen, R. et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 310, 1829\u20131836 (2013).","journal-title":"JAMA."},{"key":"24347_CR32","doi-asserted-by":"publisher","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","volume":"9","author":"WD Finkle","year":"2014","unstructured":"Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS one 9, e85805 (2014).","journal-title":"PloS one"},{"key":"24347_CR33","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jsm.12464","volume":"11","author":"AM Traish","year":"2014","unstructured":"Traish, A. M., Guay, A. T. & Morgentaler, A. Death by testosterone? We think not! The journal of sexual medicine. 11, 624\u2013629 (2014).","journal-title":"The journal of sexual medicine."},{"key":"24347_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/13685538.2014.913413","volume":"17","author":"A Morgentaler","year":"2014","unstructured":"Morgentaler, A. & Lunenfeld, B. Testosterone and cardiovascular risk: world\u2019s experts take unprecedented action to correct misinformation. Aging Male. 17, 63\u201365 (2014).","journal-title":"Aging Male."},{"key":"24347_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0211-5","volume":"12","author":"SE Borst","year":"2014","unstructured":"Borst, S. E. et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC medicine. 12, 211 (2014).","journal-title":"BMC medicine."},{"key":"24347_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2213-8587(16)30215-7","volume":"4","author":"O Onasanya","year":"2016","unstructured":"Onasanya, O., Iyer, G., Lucas, E., Singh, S. & Alexander, G. C. Association Between Exogenous Testosterone and Cardiovascular Events: An Overview of Systematic Reviews. Lancet Diabetes Endocrinol. 4, 943\u2013956 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"24347_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","volume":"13","author":"G Corona","year":"2014","unstructured":"Corona, G. et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 13, 1327\u20131351 (2014).","journal-title":"Expert Opin Drug Saf."},{"key":"24347_CR38","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","volume":"36","author":"R Sharma","year":"2015","unstructured":"Sharma, R. et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 36, 2706\u20132715 (2015).","journal-title":"Eur Heart J."},{"key":"24347_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","volume":"374","author":"PJ Snyder","year":"2016","unstructured":"Snyder, P. J. et al. Effects of Testosterone Treatment in Older Men. TNew Engl J Med. 374, 611\u2013624 (2016).","journal-title":"TNew Engl J Med."},{"key":"24347_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4239\/wjd.v8.i3.104","volume":"8","author":"G Hackett","year":"2017","unstructured":"Hackett, G., Jones, P. W., Strange, R. C. & Ramachandran, S. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes. 8, 104\u2013111 (2017).","journal-title":"World J Diabetes."},{"key":"24347_CR41","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1210\/jc.2014-1124","volume":"99","author":"B Hsu","year":"2014","unstructured":"Hsu, B. et al. Longitudinal relationships of circulating reproductive hormone with functional disability, muscle mass, and strength in community-dwelling older men: the Concord Health and Ageing in Men project. J. Clin. Endocrinol. Metab. 99, 3310\u20133318 (2014).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24347-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T23:14:06Z","timestamp":1671578046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-24347-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["24347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-24347-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"27 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5897"}}